It might not sound impressive, but I think this is great news for two reasons:
1) Even if only 10% of people respond, this is likely going to give thousands of people for whom nothing else works a drug that actually does something.
2) Nearly all existing migraine meds fall into the "triptan" class of drugs. This is an entirely new class (CGRP antagonist), and may pave the way to new treatments even if this specific iteration isn't as effective as future ones.
1) Even if only 10% of people respond, this is likely going to give thousands of people for whom nothing else works a drug that actually does something.
2) Nearly all existing migraine meds fall into the "triptan" class of drugs. This is an entirely new class (CGRP antagonist), and may pave the way to new treatments even if this specific iteration isn't as effective as future ones.